CVR 43324438Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)Benzons Allé 2, 5250 Odense SVFounded 13 Jun 2022
Compare withsimilar companiesanother companyits industry
Schroll Medical Holding ApS
CVR holds no employment figures for this company.
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Schroll Medical Holding ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
1
Annual report 2024, average
Gross profit
5M
DKK, annual report 2024
-10.5% on 2023
Result
+7M
DKK, annual report 2024
Equity
75.6M
DKK, annual report 2024
Carsten Garbo Schroll50% to under 66.7% of capital and votes, until 30 Sep 2025
Søren Dolleris Schroll50% to under 66.7% of capital and votes, until 30 Sep 2025
Søren Dolleris Schrolluntil 30 Sep 2025
No current owner is registered.
50% to under 66.7% of capital and votes28 Sep 2023 to 30 Sep 2025
50% to under 66.7% of capital and votes28 Sep 2023 to 30 Sep 2025
CVR 30078306100% of capital and votesnotified 28 Sep 202313 Jun 2022 to 28 Sep 2023
CVR 44331233100% of capital and votes28 Sep 2023 to 28 Sep 2023
Schroll Medical Holding ApS holds no Danish company now.
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 45695166100% of capital and votes19 Jun 2025 to 30 Sep 2025
CVR 39467135100% of capital and votes13 Jun 2022 to 19 Jun 2025
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2024, DKK: Gross profit 5M, Operating profit 756.8K, Result for the year 7M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2024, DKK: Total assets 111M, Equity 75.6M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2022 | 2023 | 2024 |
|---|---|---|---|
| Gross profit | 6,749 | 5,602 | 5,013 |
| Operating profit | +4,557 | +1,984 | +757 |
| Result for the year | +1,028 | +856 | +6,996 |
| Equity | 67,733 | 68,589 | 75,584 |
| Total assets | 90,979 | 100,940 | 110,994 |
| Employees (average) | 1 | 1 | 1 |
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseDemergerPaid in 9,594,000 | None | 9,594,000 | None | 10,000,000 | |
| FoundingA controlling stake in another companyPaid in 49,968,950 | None | 49,968,950 | None | 8,500,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2022 | 2023 | 2024 |
|---|---|---|---|
| Gross profit growth (vækst i bruttofortjeneste) | Not reportednote 1 | -17% | -10.5% |
| EBITDA | 6,749 | 5,602 | 5,013 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||
| Employee growth (vækst i antal ansatte) | Not reportednote 1 | 0% | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||
| Capex (investeringer i anlægsaktiver) | 8,619note 2 | 3,272note 2 | 2,636note 2 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Demerger (spaltning), as the demerged company (indskydende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Demerger (spaltning), as the receiving company (modtagende selskab)
Source: CVR, read 21 Nov 2026.
8 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående spaltning.
Virksomheden er d. 30.09.2025 opløst ved spaltning. Aktiver og gæld er som helhed overdraget til CVR-nummer 45948242 DOLLERIS SCHROLL INVEST 2025 ApS og CVR-nummer 45948234 GARBO SCHROLL INVEST 2025 ApS.
Erhvervsstyrelsen har modtaget oplysning om, at der påtænkes gennemført en spaltning af CVR-nummer: 43324438 Schroll Medical Holding ApS (indskydende ophørende), der tillige driver virksomhed under navnene Schroll Cannabinoid Technologies ApS og kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en spaltningsplan.
De øvrige deltagende virksomheder er en/flere nye virksomheder.
Kapitalejerne i CVR-nummer: 43324438 Schroll Medical Holding ApS har i enighed besluttet, at der ikke skal udarbejdes en erklæring om kreditorernes stilling i forbindelse med spaltningen. Kreditorer, hvis fordringer er stiftet forud for bekendtgørelsen om spaltningen, og for hvilke der ikke er stillet særskilt sikkerhed, kan anmelde deres fordringer senest 4 uger efter denne offentliggørelse.
Revision:
Fratrådte:
BDO Holding VII, statsautoriseret revisionsaktieselskab, den 13.08.2025.
Tiltrådte:
CVR-NR. 45719375 BDO 2025 Statsautoriseret Revisionspartnerselskab, Fælledvej 1, 5000 Odense C, den 13.08.2025.
Vedtægter ændret: 31.03.2025
Regnskabsår ændret til: 01.10 - 30.09
Omlægningsperiode: 28.09.2024 - 30.09.2025
Vedtægter ændret: 08.11.2023
Regnskabsår ændret til: 28.09 - 27.09
Omlægningsperiode: 01.10.2022 - 27.09.2023
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en fusionsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende selskaber må antages at være tilstrækkeligt sikrede efter fusionen.
Virksomheden er fusioneret med CVR-nummer: 44332604 SCHROLL 150923B ApS, der samtidigt er opløst.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående spaltning. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en spaltningsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende virksomheder må antages at være tilstrækkeligt sikrede efter spaltningen.
Aktiver og gæld er overdraget fra CVR-nummer: 30236327 Schroll Property ApS.
Vedtægter ændret: 26.08.2022
Kapitalforhøjelsen er besluttet den 26.08.2022.
kr. 1.500.000,00, indbetalt ved spaltning, kurs 639,60.
Kapitalen udgør herefter kr. 10.000.000,00.
Binavne: Schroll Cannabinoid Technologies ApS.
Stiftelsesdato: 13.06.2022.
Seneste vedtægtsdato: 13.06.2022.
Kapital:
kr. 8.500.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt ved indskud af bestemmende kapitalpost kr. 8.500.000,00 til kurs 587,87, fuldt indbetalt.
Stifter:
CVR-NR. 30078306 SCHROLL MANAGEMENT ApS, Benzons Allé 2, Dalum, 5250 Odense SV, den 13.06.2022.
Bestyrelse:
Carsten Garbo Schroll, (formand), den 13.06.2022, Mariolla Pernille Damborg Dolleris Schroll, den 13.06.2022, Stine Garbo Schroll, den 13.06.2022.
Direktion:
Søren Dolleris Schroll, den 13.06.2022.
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem eller af den samlede bestyrelse.
Revision:
CVR-NR. 20222670 BDO STATSAUTORISERET REVISIONSAKTIESELSKAB, Fælledvej 1, 5000 Odense C, den 13.06.2022.
Første regnskabsår:
01.10.2021 - 30.09.2022.
Regnskabsår:
01.10 - 30.09.
Formål:
Selskabets formål er at eje ejendomme til samt kapitalandele i datterselskaber som driver produktion, forarbejdning og salg af planter til medicinsk brug. Derudover udvikler og ejer selskabet genetik af planter til medicinsk brug.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 21 Nov 2026.
What Pro holds for Schroll Medical Holding ApS:
Have Pro? Sign in.
P-number 1028330371Benzons Allé 2, 5250 Odense SV